SPL 4.00% 12.0¢ starpharma holdings limited

What you have written is false on several levels You obviously...

  1. 9,133 Posts.
    lightbulb Created with Sketch. 789
    What you have written is false on several levels
    You obviously do not fully understand what you are reading in the context it is presented
    You need to seriously need to understand the reasons with the different strains of COVID why a 7 day endpoint may not be suitable.
    You have misinterpreted many things and IMO drawing incorrect conclusions to support some sort of conspiracy theory that TGA is some form of corrupt organisational structure and contains corrupted people.

    SPL avoided doing a full trial and were forced into doing a post market study in which it failed to meet it;s endpoint. In subgroub reprocessing analysis those over 45 YO met the endpoint.

    SPL have chosen not to release enough data to make any interpretation in regards to it . Why not release more data and graphs of full study or more details on their inferred non compliance? Why not boost shareholders value and stop any doubt?


    "Lots of criticism levelled at Starpharma for not conducting human placebo trials. But in January we got a great significant human covid treatment trial. I think this report by Cochrane Org about Paxlovid changes perspective and one really questions how TGA meekly followed FDA and gave TA temporary approval to Pfizer. Cochrane seems very unimpressed "
    Last edited by Teddyward: 29/03/24
 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
(20min delay)
Last
12.0¢
Change
-0.005(4.00%)
Mkt cap ! $49.44M
Open High Low Value Volume
12.5¢ 13.0¢ 12.0¢ $78.83K 647.3K

Buyers (Bids)

No. Vol. Price($)
7 155464 12.0¢
 

Sellers (Offers)

Price($) Vol. No.
12.5¢ 127244 2
View Market Depth
Last trade - 16.10pm 10/05/2024 (20 minute delay) ?
Last
12.0¢
  Change
-0.005 ( 4.00 %)
Open High Low Volume
12.5¢ 12.5¢ 12.0¢ 46213
Last updated 15.56pm 10/05/2024 ?
SPL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.